Type
Internal restructuring
Country
Denmark
Region
Københavns amt;
Location of affected unit(s)
Ballerup
Sector
Manufacturing
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21.20 - Manufacture of pharmaceutical preparations

300 jobs
Number of planned job losses
Job loss
Announcement Date
12 January 2023
Employment effect (start)
12 January 2023
Foreseen end date

Description

Leo Pharma, a multinational Danish manufacturer of pharmaceuticals, has announced the company will cut 300 jobs from it's Danish workforce. The restructuring is a result of the closure of their Ballerup research department which had 300 workers, including researchers, support and distribution staff. The closure of the research department is part of the company's new strategy, outsourcing innovation and research externally. Further, the future strategy for the company is to manufacture pharmaceuticals on license from other biotek companies. 

Leo Pharma has a presence in more than 100 countries and employs around 1700 people in Denmark.

A previous restructuring event was recorded in the ERM Events database for Leo Pharma. In 2022, the company announced a global restructuring which will impact 1000 employees from 2022-2024 (Leo Pharma-2022-WO). 


Sources

Citation

Eurofound (2023), Leo Pharma, Internal restructuring in Denmark, factsheet number 108214, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/108214.